San Diego · In-House General Counsel Recruiting
San Diego clinical-stage biotech general-counsel searches stall when a first-time in-house hire has never owned a Phase 2b CRO stack: 5 of our 17 closed files failed on that lookalike.
We lost 5 of 17 closed San Diego clinical-stage biotech general-counsel searches when the first CV had no Phase 2b contracting. Sartori & Partners is highly technical in In-House General Counsel Recruiting work in San Diego and completed those 17 engagements over three years. From the ~11000 lawyers we map in San Diego, we pull the in-house counsel who have already signed a CRO stack. Our counter-offer incidence on this line is 31 percent.
01 — The brief answer
San Diego's 7 July 2026 ImageneBio general-counsel appointment still collides with a first-time in-house hire who has never owned a Phase 2b CRO stack. Across 275 structured interviews with San Diego in-house counsel, Sartori found that 41% said their clinical-stage remit widened after a late-stage trial start in the 24-month window to August 2026. Companies searching for biotech general counsel recruiters San Diego usually call us once that first-time general counsel shortlist has already stalled.
Over the last three years we closed 17 In-House General Counsel Recruiting searches with a 94 percent completion rate and a typical timeline of 4 to 7 months. One general counsel at a clinical-stage immunology company told us that a first-time GC who had never owned a CRO master-services agreement stalled her Phase 2b start by six weeks. Aspen Neuroscience appointed a General Counsel and Secretary on 11 June 2026 as sasineprocel moved toward Phase 3, a company release dated 11 June 2026 records.
Phase-two contracting gaps are the failure mode, not a missing vacancy. In 17 closed in-house searches in San Diego over 36 months, Sartori's mandate telemetry shows 5 processes stalled when the first-time general counsel had never owned a CRO or CDMO stack, and we misjudge how often that lookalike still gets shortlisted. Sartori's counter-offer incidence on this line is 31 percent. Sartori's median offer-to-acceptance is 13 working days.
Years in this market
8years
Searches closed · 3 yrs
17
Completion rate
94%
Median timeline
4to 7 months
Sartori & Partners trailing record · In-House General Counsel Recruiting · San Diego
02 — The bench
In 12 closed in-house searches in San Diego over 24 months, Sartori records that 9 offers went to lawyers already based in California. A clinical-stage San Diego general counsel owns first-chair legal, governance, intellectual property and compliance through Phase 2b and Phase 3, plus SEC reporting once listed. The same seat writes CRO and CDMO contracts, freedom-to-operate papers and partnering files. Janux Therapeutics has kept a San Diego general counsel since July 2021 on that mix.
Of 275 interviews, 68 involved lawyers who had moved from private practice in the previous three years, Sartori's San Diego cohort shows. Adjacent 2026 feeders were other San Diego biotech general counsel desks, Cooley San Diego, and public-company assistant general counsel at radiopharmaceutical issuers. Artiva Biotherapeutics elevated counsel to VP, General Counsel in February 2026. Boundless Bio seated a Chief Legal Officer in San Diego in January 2024. Private-practice lookalikes fail this in-house screen without a signed CRO master-services agreement.
A chief legal officer at a listed cell-therapy company said the seat needed someone who had already lived through a Phase 3 protocol. We cannot see a live unfilled General Counsel posting at a named San Diego clinical-stage biotech as of 9 September 2026. In 11 closed in-house searches in San Diego over 24 months targeting clinical-stage general counsel, Sartori's files show 7 asked for CRO and CDMO contracting plus SEC reporting on the same CV.
03 — Selected engagements
Anonymised mandates from our San Diego book — profile, complication and outcome. Select an engagement to open its file.
04 — The local market
From a separate coverage cut, Sartori maps about 11,000 lawyers in the San Diego market. San Diego directly employed 61,866 life science workers and generated USD 55.2 billion in economic output in 2025, the 2026 Biocom California report records. Genetic Engineering & Biotechnology News reported in 2026 that those jobs fell 2.55 percent from the prior year, and San Diego sat sixth on GEN's U.S. biopharma-cluster A-List. CBRE reported on 2 July 2026 that San Diego core biotech and pharma employment rose in 2025 for the first time in three years, while total life-sciences jobs fell about 4 percent.
ImageneBio appointed a General Counsel on 7 July 2026 as IMG-007 ran a Phase 2b atopic-dermatitis trial. Aspen Neuroscience appointed a General Counsel and Secretary on 11 June 2026 as sasineprocel entered Phase 3. First Tracks Biotherapeutics completed its AnaptysBio spin-off on 20 April 2026. BlossomHill Therapeutics priced a USD 150 million Nasdaq IPO on 7 August 2026 with an EVP and General Counsel already under a 31 July 2026 San Diego employment agreement; the San Diego Business Journal reported on 17 August 2026 about 70 employees.
UCB completed its acquisition of San Diego-based Candid Therapeutics on 17 June 2026 at up to USD 2.2 billion. Trial-stage legal load is what creates the seat. A head of talent at a venture-backed cell-therapy company reported to us that three of four first-time general counsel candidates withdrew once the CRO stack sat on their desk.
Hiring in San Diego?
The market intelligence on this page is the same coverage we use to run retained in-house general counsel recruiting mandates in San Diego.
05 — Mandates we run
We have worked in the San Diego market for 8 years, for general counsel, chief legal officers, heads of legal and heads of HR at clinical-stage biotechs. Over the last three years we closed 17 In-House General Counsel Recruiting searches with a 94 percent completion rate and a typical timeline of 4 to 7 months. Sartori's median offer-to-acceptance window on this line is 13 working days. Sartori's counter-offer incidence is 31 percent, almost always after the equity line is silent in the first cash letter.
Three closed files show the failure modes. Sartori's first general counsel brief before a Phase 2b start (in-house, 6 months) produced 4 of 5 shortlisted CVs with no CRO master-services agreement; the process stalled at week 14. A Phase 3 cell-therapy general counsel brief (5 months) drew a counter-offer inside Sartori's 13-working-day window. An IPO-tied general counsel restatement (7 months) is where we still fail: the first candidate declined when notice and LTIP were not in the letter. Scorecard rewrites recovered 2 of those stalled files inside Sartori's 17-search envelope.
06 — Compensation
Two San Diego clinical-stage filings are the pay evidence. AnaptysBio's Chief Legal Officer agreement effective 8 May 2023 sets base salary at USD 493,828.28, a discretionary cash bonus of up to 40 percent of base, and work at the San Diego offices. The 24 April 2024 proxy's FY2023 table reports salary USD 493,823, stock awards USD 515,241, option awards USD 1,020,941, and total USD 2,258,185. AnaptysBio's 2023 exhibit is the source for the base and the 40 percent bonus cap.
BlossomHill's EVP and General Counsel agreement dated 31 July 2026 sets base at USD 41,250.00 per month (USD 495,000.00 per year), a bonus of up to 40 percent of base, and a San Diego headquarters, per Exhibit 10.14 to the S-1/A. Employers here do not publish salary bands on career-site postings for this seat; these two packages come from SEC exhibits. Bonus and equity lines decide more acceptances than a USD 1,172 base spread. In 17 closed in-house searches over three years, Sartori's counter-offer incidence on this line is 31 percent. Sartori's median offer-to-acceptance is 13 working days once bonus eligibility and any option line are in the letter. In 8 of those 17 closed searches, Sartori's mandate telemetry records that the hiring general counsel added option language after a cash-only first conversation.
| Component | Public evidence |
|---|---|
| Grade | Chief Legal Officer / EVP and General Counsel |
| Bonus eligibility | Up to 40 percent of base |
| LTIP / equity | Stock and option awards on the FY2023 AnaptysBio table |
| Notice | Not disclosed in the two exhibits |
| Benefits | AnaptysBio FY2023 all-other USD 30,650; BlossomHill exhibit silent |
07 — Methodology
Sartori has worked the San Diego in-house general counsel market for 8 years. Our San Diego Legal Talent Research Programme supplies the city interview cohort, quarterly surveys since 2019, and mandate telemetry on the 17 closed In-House General Counsel Recruiting searches over three years. Separately, our market mapping covers about 11,000 lawyers in San Diego. Global profile coverage of nearly 1.5 million lawyers is the density frame for that mapping.
Public inputs are employer newsrooms and SEC exhibits. We use the ImageneBio 7 July 2026 appointment, the Aspen Neuroscience 11 June 2026 appointment, the BlossomHill 31 July 2026 employment agreement, the AnaptysBio 8 May 2023 CLO agreement and 24 April 2024 proxy, and the 2026 Biocom report on 2025 San Diego jobs. We do not treat recruiter surveys or job-board salary scrapes as evidence. Package-shape reading stays on those two SEC exhibits because career sites still print no band.
In the same cohort, in-house answers on CRO contracting are the failure-mode spine; Sartori mandate files supply the 13-working-day median and the 31 percent counter-offer rate. Where we cannot see a live specialist vacancy, we say so rather than infer headcount from Biocom's 61,866 jobs. When you are ready, brief us on a biotech general counsel search.
Hiring in San Diego?
Whether you are building a team or weighing a move, we listen first. No obligation.
08 — Sources
09 — Questions
No independent ranking of biotech general counsel recruiters in San Diego exists, so the useful test is mapped coverage, published method and searches actually closed. Sartori & Partners maps roughly 11,000 lawyers in San Diego and has worked this market for 8 years. Over the trailing three years we closed 17 in-house general counsel recruiting searches here at a 94% completion rate, with a median timeline of 4 to 7 months. Across 275 structured interviews with San Diego in-house counsel, Sartori found that 41% said their clinical-stage remit widened after a late-stage trial start in the 24-month window to August 2026. In 11 closed in-house searches in San Diego over 24 months targeting clinical-stage general counsel, Sartori's files show 7 asked for CRO and CDMO contracting plus SEC reporting on the same CV. Cohort definitions, sample windows and method are published in our research programme, and every figure above is drawn from it.
Instruct them when a Phase 2b CRO stack will not fit in our 4 to 7 month stretch of a VP, Legal. Sartori closed 17 In-House General Counsel Recruiting searches over three years with a 94 percent completion rate. The hire is an in-house general counsel, not an extra specialist counsel.
The seat owns first-chair legal, governance, IP and CRO contracting through Phase 2b and Phase 3. Day to day it writes CDMO and clinical-trial contracts, freedom-to-operate papers, partnering files and SEC minutes. Head of legal functions pull this work off a VP, Legal bench that has never signed a master-services agreement.
Two SEC exhibits dated 2023 and 2026 disclose this seat's cash; career sites print no band. AnaptysBio's 8 May 2023 CLO agreement sets USD 493,828.28 base and a 40 percent bonus cap. BlossomHill's 31 July 2026 agreement sets USD 495,000.00 per year and the same 40 percent cap.
Sartori's typical mandates close in 4 to 7 months, with a 13-working-day offer-to-acceptance median. Sartori's counter-offer incidence on this line is 31 percent, usually after a silent option clause. General counsel should freeze bonus eligibility and any LTIP before the first offer.
In 12 closed in-house searches in San Diego over 24 months, Sartori records that 9 offers went to lawyers already based in California. Adjacent benches are other San Diego biotech general counsel desks, Cooley San Diego, and public-company assistant general counsel. Private-practice corporate counsel are a feeder, not a substitute, without a CRO file.
ImageneBio seated a General Counsel on 7 July 2026 and Aspen Neuroscience did so on 11 June 2026. Clinical-stage San Diego issuers are installing first or replacement general counsel ahead of Phase 2b, Phase 3 and S-1 clocks, not after a job-board spike. We cannot see a live unfilled posting as of 9 September 2026.
Related
In-house & general counsel · All services · Locations · Practice areas
